Form 4: Lucid Diagnostics Inc. Executive Receives Restricted Stock Grant

Shaun O'Neil, President and COO of Lucid Diagnostics Inc., received a grant of 400,000 restricted shares of common stock.

Summary

• Shaun O'Neil, President and COO of Lucid Diagnostics Inc., filed a Form 4 detailing changes in beneficial ownership.
• On May 7, 2024, O'Neil acquired 400,000 shares of common stock through a restricted stock grant.
• The restricted stock was granted under the Issuer's 2018 Equity Plan and has a single vesting date of May 20, 2026.
• These shares are subject to forfeiture if the required service period is not completed.
• O'Neil also holds 6,763 shares of Lucid common stock distributed by PAVmed on February 15, 2024.
• Following the transaction, O'Neil beneficially owns 526,763 shares of Lucid common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. The grant of restricted stock is generally viewed positively as it aligns executive interests with shareholder value, but it's not a major event.

Positives

• The grant of restricted stock to a key executive like the President and COO can be seen as an incentive to align their interests with the long-term success of the company.
• The vesting period of May 20, 2026, suggests a commitment from the executive to remain with the company for the foreseeable future.

Risks

• The restricted stock is subject to forfeiture if the service period is not completed, which could occur if the executive leaves the company before the vesting date.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• Shareholders may view the restricted stock grant as a positive incentive for the President and COO to drive long-term value.
• Employees may see this as a sign of confidence in the company's future.

Key Dates